Certara (CERT)
(Delayed Data from NSDQ)
$14.02 USD
-0.28 (-1.96%)
Updated Jul 9, 2024 04:00 PM ET
2-Buy of 5 2
D Value D Growth F Momentum D VGM
Certara, Inc. (CERT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.83 | $23.00 | $15.50 | 34.31% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Certara, Inc. comes to $18.83. The forecasts range from a low of $15.50 to a high of $23.00. The average price target represents an increase of 34.31% from the last closing price of $14.02.
Analyst Price Targets (9 )
Broker Rating
Certara, Inc. currently has an average brokerage recommendation (ABR) of 2.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.45 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, three are Strong Buy, representing 27.27% of all recommendations. A month ago, Strong Buy represented 27.27%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CERT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.45 | 2.45 | 2.45 | 2.45 | 2.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | Stephens | Jeffrey Garro | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | William Blair | Maxwell A Smock | Hold | Hold |
4/10/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
4/4/2024 | JMP Securities | Constantine Kyriakos Davides | Not Available | Hold |
3/1/2024 | UBS | Dan Leonard | Hold | Hold |
3/1/2024 | Not Identified | Not Identified | Hold | Hold |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
12/1/2023 | Robert W. Baird & Co. | Joe Vruwink | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.45 |
ABR (Last week) | 2.45 |
# of Recs in ABR | 11 |
Average Target Price | $18.83 |
LT Growth Rate | 10.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | 0.11 |